CardioGenesis Appoints New Board Member
SUNNYVALE, Calif., Sept. 5 /PRNewswire/ -- CardioGenesis Corporation (Nasdaq:CGCP), a leader in transmyocardial revascularization (TMR) technology, today announced the appointment of E. Walter Lange to its Board of Directors. Mr. Lange is a former Group Vice President of
Marketing, Planning and Development for Eli Lilly and Company. During his 31 years at Eli Lilly, Mr. Lange held numerous positions, including heading the group which orchestrated Eli Lilly and Company's entry into the medical device business.
``We are very pleased to have Mr. Lange join our Board of Directors. He comes to us with extensive strategic planning and corporate development experience in the medical and medical device business. Walter's broad knowledge of U.S. and international medical device markets coupled with his very valuable experience with the discovery and development of new products, will provide important strategic leadership to our business,'' said Allen W. Hill, CardioGenesis's
president and chief executive officer.
Mr. Lange served as Group Vice President of Marketing, Planning and Development for Eli Lilly and Company from 1982 to 1991. While in this position, he was a member of senior management responsible for Worldwide Pharmaceutical Marketing, including New Product Planning, Business Development and Market Research/Product Management for U.S. and O.U.S. operations. From 1976 to 1981 Mr. Lange was Vice President of Marketing, Planning and Development. This included Market Research, Product Management, and Sales Resource Planning. From 1967 to 1975, he held the positions of Director of Market Research, Product Manager, and District Sales Manager for the U.S. company. Mr. Lange started with Eli Lilly and Company International in 1960 as a Sales Representative in Canada.
Mr. Lange graduated from the University of Wisconsin with a B.S. in Pharmacy and received an M.B.A. from Marquette University. He currently serves as a board member to another technology company and consults on marketing and business development for various life science companies.
CardioGenesis Corporation, based in Sunnyvale, California, develops, manufactures and markets proprietary systems including disposable products, to perform intraoperative transmyocardial revascularization (ITMR), catheter-based percutaneous myocardial revascularization (PMR), and thoracoscopic transmyocardial revascularization (TTMR) to treat patients afflicted with debilitating angina. CardioGenesis(TM) probes and catheter systems deliver laser energy to create channels in the oxygen-deprived (ischemic) regions of the heart muscle myocardium). CardioGenesis holds patents for the system and method of percutaneous myocardial revascularization, U.S. Patent Number 5,389,096; the method for intraoperative myocardial device revascularization, U.S. Patent Number 5,380,316; and other patents in the field of transmyocardial revascularization. For more information on the company and their products, visit their website at ww.cardiogenesis.com.
For more information on CardioGenesis Corporation via fax, dial 800-PRO-INFO, code CGCP. |
